ArticleJournal of the American Heart Association2026

Impact of Mavacamten Approval on Septal Reduction Therapy Rates in Hypertrophic Cardiomyopathy.

Ramzi Ibrahim et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.